BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 21767697)

  • 1. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
    Burgueño-Montañés C; Pérez-Álvarez R
    Arch Soc Esp Oftalmol; 2011 Jun; 86(6):193-5. PubMed ID: 21767697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
    [No Abstract]   [Full Text] [Related]  

  • 4. Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C.
    Adams S; Ostermeier M
    Optometry; 2010 Nov; 81(11):580-6. PubMed ID: 20655283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.
    Such Díaz A; Barrueco N; Esteban Alba C; Escobar Rodríguez I
    Farm Hosp; 2011; 35(2):93-4. PubMed ID: 20615736
    [No Abstract]   [Full Text] [Related]  

  • 7. Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.
    Fouad YM; Khalaf H; Ibraheem H; Rady H; Helmy AK
    Int J Infect Dis; 2012 Jan; 16(1):e67-71. PubMed ID: 22115957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
    Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
    Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bilateral non-arteritic ischemic optic neuropathy during treatment of viral hepatitis C with pegylated interferon and Ribavirin].
    Iferkhass S; Elasri F; Chatioui S; Khoyaali A; Bargach T; Reda K; Oubaaz A
    J Fr Ophtalmol; 2015 Jan; 38(1):34-40. PubMed ID: 25533994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening.
    Vujosevic S; Tempesta D; Noventa F; Midena E; Sebastiani G
    Hepatology; 2012 Aug; 56(2):455-63. PubMed ID: 22331668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness and safety of antiviral therapy of military personnel suffering from chronic hepatitis C].
    Zhdanov KV; Gusev DA; Kozlov KV; Shishkin MK; Sukachev VS; Shakhmanov DM; Zhabrov SS
    Voen Med Zh; 2015 Apr; 336(4):44-9. PubMed ID: 26454938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pegylated intereferon hematological safety in comparison with standard].
    Fazylov VKh; Manapova ÉR; Tkacheva SV; Sozinova IuM
    Eksp Klin Gastroenterol; 2012; (6):96-9. PubMed ID: 23402198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin.
    Schulman JA; Liang C; Kooragayala LM; King J
    Ophthalmology; 2003 Feb; 110(2):437-42. PubMed ID: 12578794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal nerve fibre layer defects associated with cotton-wool spots in patients with interferon retinopathy.
    Hara K; Tanito M; Ohira A
    Acta Ophthalmol; 2012 Mar; 90(2):e158-60. PubMed ID: 21649866
    [No Abstract]   [Full Text] [Related]  

  • 16. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
    Hu CC; Chien RN
    Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
    [No Abstract]   [Full Text] [Related]  

  • 17. [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].
    Iwasaki Y; Ikeda F; Yamamoto K
    Nihon Rinsho; 2011 May; 69 Suppl 4():215-20. PubMed ID: 22096922
    [No Abstract]   [Full Text] [Related]  

  • 18. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
    Slim J; Afridi MS
    Infect Dis Clin North Am; 2012 Dec; 26(4):917-29. PubMed ID: 23083824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ophthalmologic findings in hepatitis C patients treated with pegylated interferon α-2b and ribavirin.
    Novelli FJ; Przysiezny A; Rosa EL; Garcia RF; Nóbrega MJ
    Arq Bras Oftalmol; 2014; 77(3):178-81. PubMed ID: 25295906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
    Kang HM; Park MJ; Hwang JM; Kim JW; Jeong SH
    Korean J Hepatol; 2009 Jun; 15(2):209-15. PubMed ID: 19581773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.